Related Experiment Video
Updated: May 24, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Current anticoagulant safety.
Gentian Denas1, Vittorio Pengo
1University of Padua School of Medicine, Cardiology Clinic, Thrombosis Center, Department of Cardiothoracic and Vascular Sciences, Padua, Italy.
Expert Opinion on Drug Safety
|March 7, 2012
Summary
New anticoagulants show promising safety profiles, offering an alternative to traditional therapies like warfarin. These novel agents are expected to become standard for preventing blood clots and strokes.
Area of Science:
- Pharmacology
- Cardiology
- Hematology
Background:
- Traditional anticoagulants (heparin, warfarin) have safety limitations, primarily bleeding risks.
- Effective anticoagulation requires balancing efficacy with bleeding risk, necessitating careful management.
- Advances in anticoagulation management include monitoring, patient education, and specialized centers.
Purpose of the Study:
- To review and compare the safety of existing anticoagulants with newer agents.
- To highlight the evolving landscape of antithrombotic therapies.
Main Methods:
- Literature review and synthesis of safety data from clinical trials.
- Comparative analysis of adverse events associated with different anticoagulant classes.
Main Results:
- Novel anticoagulants demonstrate encouraging safety profiles in clinical trials.
- The risk of bleeding is a primary concern with all anticoagulation therapies.
- Improved management strategies enhance the safety of anticoagulation therapy.
Conclusions:
- Novel anticoagulant agents show potential to rival established treatments for thromboprophylaxis, treatment, and stroke prevention in atrial fibrillation.
- Emerging clinical trial data supports the efficacy and safety of new anticoagulants.
- These novel agents are poised to become integral to antithrombotic drug regimens.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:13Therapeutic Index
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...